NEW YORK – PerkinElmer and FDNA announced a licensing and comarketing agreement this week under which the firms will combine their respective genomic and next-generation phenotyping (NGP) technologies to help diagnose rare diseases.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.